



Published in final edited form as:

*Bioorg Med Chem Lett.* 2018 November 01; 28(20): 3320–3323. doi:10.1016/j.bmcl.2018.09.011.

## Antimicrobial 1,3,4-trisubstituted-1,2,3-triazolium salts


James T. Fletcher, Jill M. Sobczyk, Sarah C. Gwazdacz, and Aaron J. Blanck

Department of Chemistry, Creighton University, 2500 California Plaza, Omaha, NE 68178, U.S.A.

### Abstract

A series of 1,3,4-trisubstituted-1,2,3-triazolium bromide salts were prepared by efficient two-step sequences of azide-alkyne cycloaddition and benzylic substitution. The antimicrobial activity of each triazolium salt and correlating triazole precursor was evaluated using a minimum inhibitory concentration (MIC) assay. MIC activities as low as 1  $\mu\text{M}$  against Gram-positive bacteria, 8  $\mu\text{M}$  against Gram-negative bacteria and 4  $\mu\text{M}$  against fungi were observed for salt analogs, while neutral triazoles were inactive. Analogs representing selective and broad-spectrum antimicrobial activity were each identified. MIC structure-activity relationships observed within this motif indicate that the presence of cationic charge and balance of overall hydrophobicity are strongly impactful, while benzyl vs. aryl substituent identity and variation of substituent regiochemistry are not.

### Abstract



### Keywords

Antibacterial; antifungal; benzylation; cycloaddition; organic salt

Quaternary ammonium compounds (QACs) are an exemplary class of widely utilized, fully synthetic antibiotics.<sup>1</sup> Representative analogs such as benzalkonium chloride have been used as antiseptics for nearly a century. While such compounds take structural inspiration from natural products such as berberine,<sup>2</sup> norspermidine<sup>3</sup> and cationic antimicrobial peptides,<sup>4–8</sup> the fully synthetic nature of QACs permit relatively simple structural variations that are

James T. Fletcher - jamesfletcher@creighton.edu.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

necessary to complete the structure-activity relationship (SAR) profiling studies needed for optimizing therapeutic properties. The cationic nitrogen atoms defining of this class of antimicrobial compounds include benzylic, aliphatic and aromatic ammonium centers. Among the heterocycles representing aromatic ammonium analogs are pyridinium,<sup>9</sup> imidazolium<sup>10,11</sup> and 1,2,4-triazolium<sup>10,12</sup> units.

While modification of simple hydrophobic groups around central ammonium center(s) in a small molecule motif may seem relatively simplistic from a structural diversity perspective, particularly in comparison to the frequently elaborate structures represented by natural product antibiotics, this general synthetic approach has been successfully utilized to prepare many effective and widely used QAC compounds and remains an active area of contemporary research.<sup>1,13,14</sup> Analogs of the 1,3,4-trisubstituted-1,2,3-triazolium salt motif have been shown to display ionic liquid,<sup>15,16</sup> catalytic,<sup>17</sup> antileishmanial,<sup>18</sup> and antimalarial<sup>10</sup> properties. Surprisingly, although 1,2,4-triazolium salts have been demonstrated as effective heterocyclic components of QAC compounds<sup>10,12</sup> and examples of antimicrobial 1,2,3-triazolium-functionalized biopolymers have been recently reported,<sup>19–21</sup> studies describing the general antimicrobial properties of aliphatic 1,2,3-triazolium salts themselves are lacking.

With the recent advent of the “click chemistry” era, founded upon the Sharpless-Meldal copper-catalyzed azide-alkyne coupling (CuAAC) reaction first reported in 2002,<sup>22,23</sup> the efficient preparation of 1,2,3-triazole compounds with diverse peripheral functionality is now commonplace.<sup>24,25</sup> Hence, preparing QAC analogs deriving from this heterocyclic motif and defining general SAR antimicrobial trends stands as an attractive target for developing new antimicrobial compounds. As an initial effort to define general SAR profiles for this class of molecular organic salts, the synthesis and antimicrobial evaluation of amphiphilic 1,3,4-trisubstituted-1,2,3-triazolium bromides with systematic variations in hydrophobicity, regiochemistry and substituent attachment is presented herein.

A representative family of 1,4-disubstituted-1,2,3-triazole and 1,3,4-trisubstituted-1,2,3-triazolium compounds was prepared using the three established reaction sequences illustrated in Figure 1. Those 1,4-disubstituted-1,2,3-triazole analogs with aryl substitution at the N1 position were prepared from direct copper-catalyzed alkyne-azide cycloaddition (CuAAC)<sup>24</sup> (method A) between commercially available alkynes and aryl azides prepared using the Sandmeyer reaction.<sup>26</sup> Those 1,4-disubstituted-1,2,3-triazole analogs with N1 benzylic substitution were prepared using a tandem CuAAC method,<sup>15,27</sup> where commercially available benzyl bromide and sodium azide were used to prepare the organic azide reactant in the presence of the CuAAC reactant and catalyst (method B), achieving a two-step reaction sequence in a one-pot reaction. The 1,5-disubstituted-1,2,3-triazole analog was prepared from base-catalyzed conditions<sup>28</sup> (method C) that promote 1,5-regioselective acetylide-alkyne cycloaddition using commercially available alkyne and prepared aryl azide reactants.

Each 1,2,3-triazole analog was successfully converted to a 1,3,4-trisubstituted-1,2,3-triazolium salt by substitution reaction at the N3 position,<sup>15,17</sup> resulting in organic salts with quaternized ammonium centers. The majority of these quaternization reactions proceeded in

high yield when an excess of benzyl bromide or 4-*tert*-butylbenzyl bromide reactant was used, with the exception of **7** having bulky C4 phenyl substitution that significantly reduced benzylation yields due to steric inhibition. Following evaporation of reaction solvent, pure triazolium bromide salts were isolated from a hexane trituration that removed unreacted neutral organics with minimal loss of ionic salt products. Hence, the target compounds in this study were accessible in good yield using only 2–3 overall reaction steps.

The antimicrobial properties of these triazole compounds and triazolium salts were evaluated using microdilution minimum inhibitory concentration assays as described in the CLSI protocol for bacteria<sup>29</sup> and yeasts.<sup>30</sup> BSL1 strains of Gram-positive bacteria (*Bacillus subtilis*, *Staphylococcus epidermidis*), Gram-negative bacteria (*Escherichia coli*, *Enterobacter aerogenes*) and yeast (*Candida albicans*, *Saccharomyces cerevisiae*) were selected as model organisms for the desired general antimicrobial profiling. Assays were run in triplicate and minimum inhibitory concentration (MIC) values were defined by observing the optical transparency of the most dilute well suppressing microbial growth. Two commercial QAC class antibiotics, cetylpyridinium chloride and benzalkonium chloride, were used as controls.

Assay results are summarized in Table 1. Among this limited family of compounds, examples of analogs displaying both selective and broad-spectrum antimicrobial activity were observed. While it was unsurprising that as representatives of the QAC structural motif these 1,3,4-trisubstituted-1,2,3-triazolium bromide salts did display antibiotic properties, the significant influence that simple substituent variations had on both selectivity and overall antimicrobial activity among this group of analogs was unexpected. None of the neutral 1,2,3-triazole compounds **1–8** showed measurable MIC values, and charged analogs **9, 12, 15, 21** and **23** possessing minimal hydrophobicity among the salts studied also lacked measurable MIC activity.

Analogs in the series possessing a moderate amount of peripheral hydrophobicity were observed to exert the most selective antimicrobial activity. **16** and **18** displayed greater than 50-fold selectivity towards the Gram-positive bacteria tested relative to the Gram-negative bacteria and fungi, with **10, 22** and **24** also showing such selectivity at slightly lower discrepancy. Analogs representing the maximum amount of hydrophobicity in the series, **14** and **20**, showed expanded bioactivity towards both Gram-positive bacteria and fungi but not Gram-negative bacteria. An increased degree of broad-spectrum antimicrobial activity against all three classes of pathogens was observed for **11, 13, 17** and **19**, which possessed more hydrophobicity than the Gram-positive selective analogs (**10, 16, 18**) but less hydrophobicity than those analogs that discriminated against Gram-negative bacteria (**14, 20**).

MIC potency for this family of triazolium salts was observed as low as 1  $\mu\text{M}$  (0.5  $\mu\text{g/ml}$ ) against Gram-positive bacteria, 4  $\mu\text{M}$  (2  $\mu\text{g/ml}$ ) against fungi and 8  $\mu\text{M}$  (4  $\mu\text{g/ml}$ ) against Gram-negative bacteria. In comparison to the QAC controls cetylpyridinium chloride and benzalkonium chloride, these MIC values were slightly more potent against Gram-negative bacteria and slightly less potent against Gram-positive bacteria and fungus under the conditions assayed. Benzyl vs. aryl substituent identity at the N1 position was insignificant,

as the MIC results of **9–14** largely mirrored **15–20**. Regiochemistry of diaryl attachment was also observed to be inconsequential, with the regioisomer pairs **21/23** and **22/24** displaying analogous potency against the set of organisms tested.

Evaluation of this data set enables preliminary structure-activity relationship trends to be defined for this family of molecular 1,3,4-trisubstituted-1,2,3-triazolium bromide salts: (1) the cationic nature of the 1,2,3-triazolium salt is necessary for antimicrobial potency, as none of the neutral 1,2,3-triazole analogs are significantly active (MIC  $\geq$  250  $\mu$ M for each); (2) increasing hydrophobicity at the N3 and C4 positions generally leads to increased potency against Gram-positive bacteria and fungi, while sufficient but not excessive hydrophobicity is ideal for maximum potency against Gram-negative bacteria; (3) no significant differences in potency are observed between aryl and benzyl substitution at the N1 position; and (4) no significant differences in potency are observed for regioisomer analogs with varying 1,4- vs. 1,5-diaryl substitution.

With the dominant driving force for potency being cationic amphiphilic properties, it is hypothesized that this class of molecules exerts antimicrobial activity via interaction with and destabilization of the cell membranes of target organisms.<sup>31,32</sup> Against both Gram-positive bacteria and fungi, antimicrobial activity correlated with increasing hydrophobicity within the range of analogs examined. In contrast, against Gram-negative bacteria maximum potency was observed for analogs possessing a combination of moderate hydrophobicity at the triazole N3 and C4 positions relative to those displaying broad-spectrum effects. A decrease in QAC toxicity towards Gram-negative bacteria relative to Gram-positive bacteria is commonly observed<sup>13</sup> due to the presence of their outer membrane, which in this case may be preventing the larger sized triazolium analogs from reaching and destabilizing the inner membrane of such organisms.

This investigation demonstrates that simple 1,3,4-trisubstituted-1,2,3-triazolium bromide salts display significant antimicrobial activity against model Gram-positive bacteria, Gram-negative bacteria and fungi in a substituent-dependent manner and establishes a preliminary SAR profile for this class of molecular organic salts. Each analog in this study was prepared efficiently from a sequence of cycloaddition and substitution reaction steps. Analogues representing both selective and broad-spectrum activity were each identified among this family of compounds. While this limited set of analogs allowed a general antibiotic SAR to be defined, a more comprehensive survey of substituents is warranted. Future studies will attempt to optimize both the potency and selectivity of bioactivity by embracing the facile synthetic variation of substituents at the 1-, 3- and 4- positions, as well as examine the antimicrobial properties of select analogs against drug-resistant and clinically-relevant pathogen strains.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

This publication was made possible by grants from the National Institute for General Medical Science (NIGMS) (5P20GM103427), a component of the National Institutes of Health (NIH), and its contents are the sole responsibility of the authors and do not necessarily represent the official views of NIGMS or NIH.


## References

1. Minbiole KPC, Jennings MC, Ator LE, et al. From antimicrobial activity to mechanism of resistance: the multifaceted role of simple quaternary ammonium compounds in bacterial eradication. *Tetrahedron*. 2016;72(25):3559–3566. doi:10.1016/j.tet.2016.01.014.
2. Šeráková M, Košálová D. Antimicrobial activity of berberine—a constituent of *Mahonia aquifolium*. *Folia Microbiol (Praha)*. 2002;47(4):375–378. doi:10.1007/BF02818693. [PubMed: 12422513]
3. Böttcher T, Kolodkin-Gal I, Kolter R, Losick R, Clardy J. Synthesis and activity of biomimetic biofilm disruptors. *J Am Chem Soc*. 2013;135(8):2927–2930. doi:10.1021/ja3120955. [PubMed: 23406351]
4. Bechara C, Sagan S. Cell-penetrating peptides: 20 years later, where do we stand? *FEBS Lett*. 2013;587(12):1693–1702. doi:10.1016/j.febslet.2013.04.031. [PubMed: 23669356]
5. Fernandez-Lopez S, Kim HS, Choi EC, et al. Antibacterial agents based on the cyclic D,L-alpha-peptide architecture. *Nature*. 2001;412(6845):452–455. doi:10.1038/35086601. [PubMed: 11473322]
6. Fletcher JT, Finlay JA, Callow ME, Callow JA, Ghadiri MR. A Combinatorial Approach to the Discovery of Biocidal Six-Residue Cyclic d,l- $\alpha$ -Peptides Against the Bacteria Methicillin-Resistant *Staphylococcus aureus* (MRSA) and *E. coli* and the Biofouling Algae *Ulva linza* and *Navicula perminuta*. *Chem - A Eur J*. 2007;13(14):4008–4013. doi:10.1002/chem.200601583.
7. Saar K, Lindgren M, Hansen M, et al. Cell-penetrating peptides: A comparative membrane toxicity study. *Anal Biochem*. 2005;345(1):55–65. doi:10.1016/j.ab.2005.07.033. [PubMed: 16137634]
8. Powers JPS, Hancock REW. The relationship between peptide structure and antibacterial activity. *Peptides*. 2003;24(11):1681–1691. doi:10.1016/j.peptides.2003.08.023. [PubMed: 15019199]
9. Forman ME, Jennings MC, Wuest WM, Minbiole KPC. Building a Better Quaternary Ammonium Compound (QAC): Branched Tetracationic Antiseptic Amphiphiles. *ChemMedChem*. 2016;11(13):1401–1405. doi:10.1002/cmdc.201600176. [PubMed: 27245743]
10. Vlahakis JZ, Mitu S, Roman G, Rodriguez EP, Crandall IE, Szarek WA. The anti-malarial activity of bivalent imidazolium salts. *Bioorganic Med Chem*. 2011;19(21):6525–6542. doi:10.1016/j.bmc.2011.06.002.
11. Crandall IE, Zhao B, Vlahakis JZ, Szarek WA. The interaction of imidazole-, imidazolium-, and tetrazolium-containing compounds with DNA. *Bioorganic Med Chem Lett*. 2013;23(5):1522–1528. doi:10.1016/j.bmcl.2012.11.106.
12. Luo Y, Lu Y-H, Gan L-L, et al. Synthesis, Antibacterial and Antifungal Activities of Novel 1,2,4-Triazolium Derivatives. *Arch Pharm (Weinheim)*. 2009;342(7):386–393. doi:10.1002/ardp.200800221. [PubMed: 19544478]
13. Jennings MC, Minbiole KPC, Wuest WM. Quaternary Ammonium Compounds: An Antimicrobial Mainstay and Platform for Innovation to Address Bacterial Resistance. *ACS Infect Dis*. 2016;1(7):288–303. doi:10.1021/acsinfecdis.5b00047.
14. Jennings MC, Buttar BA, Minbiole KPC, Wuest WM. Bioorganic Investigation of Multicationic Antimicrobials to Combat QAC-Resistant *Staphylococcus aureus*. *ACS Infect Dis*. 2016;1(7):304–309. doi:10.1021/acsinfecdis.5b00032.
15. Fletcher JT, Keeney ME, Walz SE. 1-Allyl- and 1-benzyl-3-methyl-1,2,3-triazolium salts via tandem click transformations. *Synthesis (Stuttg)*. 2010;(19):3339–3345. doi:10.1055/s-0030-1257909.
16. Yan F, Lartey M, Jariwala K, et al. Toward a materials genome approach for ionic liquids: Synthesis guided by ab initio property maps. *J Phys Chem B*. 2014;118(47):13609–13620. doi:10.1021/jp506972w. [PubMed: 25356930]

17. Donnelly KF, Petronilho A, Albrecht M. Application of 1,2,3-triazolylienes as versatile NHC-type ligands: synthesis, properties, and application in catalysis and beyond. *Chem Commun.* 2013;49(12):1145–1159. doi:10.1039/C2CC37881G.
18. Stroppa PHF, Antinarelli LMR, Carmo AML, Gameiro J, Coimbra ES, da Silva AD. Effect of 1,2,3-triazole salts, non-classical bioisosteres of miltefosine, on *Leishmania amazonensis*. *Bioorganic Med Chem.* 2017;25(12):3034–3045. doi:10.1016/j.bmc.2017.03.051.
19. Tan W, Zhang J, Luan F, et al. Synthesis, characterization, and antifungal evaluation of novel 1,2,3-triazolium-functionalized starch derivative. *Int J Biol Macromol.* 2017;101:845–851. doi:10.1016/j.ijbiomac.2017.03.171. [PubMed: 28373043]
20. Tan W, Li Q, Dong F, et al. Novel cationic chitosan derivative bearing 1,2,3-triazolium and pyridinium: Synthesis, characterization, and antifungal property. *Carbohydr Polym.* 2018;182(10 2017):180–187. doi:10.1016/j.carbpol.2017.11.023. [PubMed: 29279113]
21. Shyam R, Charbonnel N, Job A, et al. 1,2,3-Triazolium-Based Cationic Amphiphilic Peptoid Oligomers Mimicking Antimicrobial Helical Peptides. *ChemMedChem.* 2018;13(15):1513–1516. doi:10.1002/cmdc.201800273. [PubMed: 29917316]
22. Rostovtsev VV, Green LG, Fokin VV, Sharpless KB. A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective “Ligation” of Azides and Terminal Alkynes. *Angew Chemie Int Ed* 2002;41(14):2596–2599. doi:10.1002/15213773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4.
23. Tornøe CW, Christensen C, Meldal M. Peptidotriazoles on solid phase: [1,2,3]Triazoles by regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. *J Org Chem.* 2002;67(9):3057–3064. doi:10.1021/jo011148j. [PubMed: 11975567]
24. Meldal M, Tornøe CW. Cu-Catalyzed Azide-Alkyne Cycloaddition. *Chem Rev.* 2008;108(8):2952–3015. doi:10.1021/cr0783479. [PubMed: 18698735]
25. Totobenazara J, Burke AJ. New click-chemistry methods for 1,2,3-triazoles synthesis: Recent advances and applications. *Tetrahedron Lett.* 2015;56(22):2853–2859. doi:10.1016/j.tetlet.2015.03.136.
26. Brase S, Gil C, Knepper K, Zimmermann V. Organic azides: An exploding diversity of a unique class of compounds. *Angew Chemie - Int Ed* 2005;44(33):5188–5240. doi:10.1002/anie.200400657.
27. Indapurkar A, Henriksen B, Tolman J, Fletcher J. Evaluation of triazole-chelated lanthanides as chemically stable bioimaging agents. *J Pharm Sci.* 2013;102(8). doi:10.1002/jps.23616.
28. Kwok SW, Fotsing JR, Fraser RJ, Rodionov VO, Fokin VV. Transition-Metal-Free Catalytic Synthesis of 1,5-Diaryl-1,2,3-triazoles. *Org Lett.* 2010;12(19):4217–4219. doi:10.1021/ol101568d. [PubMed: 20825167]
29. CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Tenth Edition. CLSI document M07-A10. Wayne, PA: Clinical and Laboratory Standards Institute; 2015 Vol 35; 2015.
30. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard - Third Edition. CLSI document M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
31. Denyer SP. Mechanisms of action of antibacterial biocides. *Int Biodeterior Biodegrad.* 1995;36(3–4):227–245. doi:10.1016/0964-8305(96)00015-7.
32. Vieira DB, Carmona-Ribeiro AM. Cationic lipids and surfactants as antifungal agents: Mode of action. *J Antimicrob Chemother.* 2006;58(4):760–767. doi:10.1093/jac/dkl312. [PubMed: 16885181]


### Highlights

- Aliphatic 1,3,4-trisubstituted-1,2,3-triazolium salts show antimicrobial properties
- Analogs representing selective and broad-spectrum antimicrobial activity identified
- Potency strongly influenced by hydrophobicity; regiochemistry less impactful
- Triazolium salts prepared efficiently using click and benzylation reaction steps



**Figure 1.** Direct (A, C) and tandem (B) two-step methods to prepare 1,3,4-trisubstituted 1,2,3-triazolium salts. The numbering scheme used for substituent identification is shown.






**Figure 2.** Identities of the neutral 1,2,3-triazole analogs in this study. Isolated yields are noted.

Table 1.

## Survey of Triazolium Salt Antimicrobial Activity

											
Analog				Yield*	Minimum Inhibitory Concentration (µM)**						
	R <sup>1</sup> =	R <sup>2</sup> =	R <sup>3</sup> =		B.S.	S.E.	E.C.	E.A.	C.A.	S.C.	
9	CH <sub>2</sub> Ph	<i>n</i> -C <sub>4</sub> H <sub>9</sub>	CH <sub>2</sub> Ph	96%	>250	>250	>250	>250	>250	>250	
10	CH <sub>2</sub> Ph	<i>n</i> -C <sub>8</sub> H <sub>17</sub>	CH <sub>2</sub> Ph	98%	8	8	>250	>250	250	250	
11	CH <sub>2</sub> Ph	<i>n</i> -C <sub>12</sub> H <sub>25</sub>	CH <sub>2</sub> Ph	95%	2	4	16	16	16	16	
12	CH <sub>2</sub> Ph	<i>n</i> -C <sub>4</sub> H <sub>9</sub>	CH <sub>2</sub> Ph(4-tBu)	98%	8	8	>250	>250	250	250	
13	CH <sub>2</sub> Ph	<i>n</i> -C <sub>8</sub> H <sub>17</sub>	CH <sub>2</sub> Ph(4-tBu)	98%	1	2	31	31	8	16	
14	CH <sub>2</sub> Ph	<i>n</i> -C <sub>12</sub> H <sub>25</sub>	CH <sub>2</sub> Ph(4-tBu)	95%	2	2	250	250	8	16	
15	Ph(4-CH <sub>3</sub> )	<i>n</i> -C <sub>4</sub> H <sub>9</sub>	CH <sub>2</sub> Ph	93%	>250	>250	>250	>250	>250	>250	
16	Ph(4-CH <sub>3</sub> )	<i>n</i> -C <sub>8</sub> H <sub>17</sub>	CH <sub>2</sub> Ph	89%	4	8	>250	>250	250	250	
17	Ph(4-CH <sub>3</sub> )	<i>n</i> -C <sub>12</sub> H <sub>25</sub>	CH <sub>2</sub> Ph	97%	1	2	8	8	8	8	
18	Ph(4-CH <sub>3</sub> )	<i>n</i> -C <sub>4</sub> H <sub>9</sub>	CH <sub>2</sub> Ph(4-tBu)	93%	4	4	250	>250	250	250	
19	Ph(4-CH <sub>3</sub> )	<i>n</i> -C <sub>8</sub> H <sub>17</sub>	CH <sub>2</sub> Ph(4-tBu)	95%	2	2	16	16	4	8	
20	Ph(4-CH <sub>3</sub> )	<i>n</i> -C <sub>12</sub> H <sub>25</sub>	CH <sub>2</sub> Ph(4-tBu)	97%	2	2	250	250	4	4	
21	Ph(4-CH <sub>3</sub> )	Ph	CH <sub>2</sub> Ph	48%	>250	>250	>250	>250	>250	>250	
22	Ph(4-CH <sub>3</sub> )	Ph	CH <sub>2</sub> Ph(4-tBu)	49%	8	8	>250	>250	>250	>250	
23	CH <sub>2</sub> Ph	Ph	Ph(4-CH <sub>3</sub> )	94%	>250	>250	>250	>250	>250	>250	
24	CH <sub>2</sub> Ph(4-tBu)	Ph	Ph(4-CH <sub>3</sub> )	93%	16	16	>250	>250	>250	>250	
Cetylpyridinium chloride					1	0.2	25	16	4	1	
Benzalkonium chloride					4	1	62	62	62	12	

\* Isolated yields indicated.

\*\* Concentrations surveyed: Initial range was 250, 125, 62, 31, 16, 8, 4 and 2 µM, repeated at 10x dilution for potent analogs.

B.S. = *Bacillus subtilis* (ATCC 6051); S.E. = *Staphylococcus epidermidis* (ATCC 14990); E.C. = *Escherichia coli* (ATCC 25922); E.A. = *Enterobacter aerogenes* (ATCC 13048); C.A. = *Candida albicans* (ATCC 90028); S.C. = *Saccharomyces cerevisiae* (ATCC 9763).